Drug Trial Radar · NCT05919537
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Sep 6, 2023
Primary completion
Mar 1, 2031
Study completion Mar 1, 2031
Sponsor
- Lead sponsor
- Hummingbird BioscienceIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
Conditions
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
HMBD-001Drug
HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
DocetaxelDrug
Docetaxel 75 mg/m\^2 IV once every 3 weeks
Nab-paclitaxelDrug
Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
GemcitabineDrug
Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Nature of Adverse Events (AEs)Time frame: From the time the ICF is signed until 30 days after last dose of study treatment
- Arm A and B only: Incidence and nature of dose-limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Arm A: During the first four weeks of study treatment Arm B: During the first three weeks of study treatment
- Objective Response Rate (ORR) by RECIST V1.1Time frame: Up to 24 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
GenesisCare North Shore
Sydney, New South Wales, Australia
ICON Cancer Centre South Brisbane
Brisbane, Queensland, Australia
Southern Oncology Clinical Research Unit
Adelaide, South Australia, Australia
Cabrini Health
Malvern, Victoria, Australia
Linear Clinical Research
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.